Editorial comment.
作者信息
Rini Brian I, Shah Shetal N
出版信息
Urology. 2010 May;75(5):1114-5; author reply 1115. doi: 10.1016/j.urology.2009.07.1291.
Abstract
摘要
相似文献
1
Editorial comment.
Urology. 2010 May;75(5):1114-5; author reply 1115. doi: 10.1016/j.urology.2009.07.1291.
2
Editorial comment.
Urology. 2010 May;75(5):1114; author reply 1115. doi: 10.1016/j.urology.2009.07.1290.
3
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.
4
Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20.
5
Trials probe new agents for kidney cancer.
JAMA. 2006 Jul 12;296(2):155-7. doi: 10.1001/jama.296.2.155.
6
Therapy for metastatic RCC--questions remain.
Nat Rev Urol. 2009 Nov;6(11):580-1. doi: 10.1038/nrurol.2009.210.
7
[Renal cell carcinoma].
Gan To Kagaku Ryoho. 2010 Jan;37(1):29-31.
8
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Urology. 2010 May;75(5):1108-13.e1. doi: 10.1016/j.urology.2009.06.105. Epub 2009 Nov 20.
9
Renal-cell carcinoma--molecular pathways and therapies.
N Engl J Med. 2007 Jan 11;356(2):185-7. doi: 10.1056/NEJMe068263.
10
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
BJU Int. 2007 May;99(5 Pt B):1223-9. doi: 10.1111/j.1464-410X.2007.06814.x.
Zotero 插件